Skip to NavigationSkip to content


New ICER report reveals most cost-effective rheumatoid arthritis therapies

The Institute for Clinical and Economic Review (ICER) has unveiled a new report comparing the clinical efficacy and cost-effectiveness of three JAK inhibitors for treating rheumatoid arthritis (RA): AbbVie’s Rinvoq (upadacitinib), Pfizer’s Xeljanz (tofacitinib), and Eli Lilly’s Olumiant (baricitinib).

Head-to-head data revealed that Rinvoq demonstrated “statistically-significant but modestly higher rates of disease remission and improvement in other important outcomes” compared to AbbVie’s best-selling drug Humira; the report asserted that it could be assumed with “moderate certain

Top Ten most popular articles on this week

Happy Friday! With the weekend within reach, check out our run-down of the top ten most popular articles on this week, including Keytruda's liver cancer failure, a "game-changing osteoasrthritis treatment, AstraZeneca's retirement of the MedImmune brand, and the promise of the first new asthma pill in two decades.

10. Poland and Slovenia included in US-EU mutual recognition agreement

Pfizer overhauls Xeljanz study over concerns of increased risk of pulmonary embolism and death

Pfizer is set to overhaul the dosing groups in its ongoing study of Xeljanz (tofacitinib) after an evaluation from a Rheumatology Data Safety Monitoring Board (DSMB) highlighted safety concerns in the higher of the two doses.

The Board identified a higher risk of pulmonary embolism in patients taking 10mg twice daily than in patients in the tumour necrosis factor inhibitor (TNFi) control group, prompting Pfizer to announce plans to transfer these patients to the lower 5mg twice daily dosing group.

Pfizer notches two EU approvals, including Herceptin biosimilar

Pfizer is patting itself on the back after securing two new approvals in Europe within 24 hours: Xeljanz (tofacitinib citrate) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients for whom other therapies have proved unsuitable, and its biosimilar Trazimera (trastuzumab) in the treatment of human epidermal growth factor (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

The decision on Xeljanz, which makes it the first and only oral therapy and Janus kinase (JAK) inhibit

Pfizer's Xeljanz scores EU approval for active psoriatic arthritis

Pfizer has announced that the European Commission (EC) has approved Xeljanz in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.

Pfizer's Xeljanz becomes first JAK inhibitor approved in US for active ulcerative colitis

Pfizer has revealed that its Janus kinase (JAK) inhibitor Xeljanz (tofacitinib) has received FDA approval for the treatment of adult patients with moderately to severely active ulcerative colitis, making it the first and only therapy of its kind available for the condition in the US.

FDA approves Pfizer's Xeljanz for psoriatic arthritis

Pfizer has revealed that the FDA has passed marketing approval for Xeljanz (tofacitinib) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).

Pfizer launches legal action to block Xeljanz copies in India

Pfizer has pre-emptively sued a number of India-based drug companies including Sun Pharma and Zydus Cadila to block any attempts to copy its rheumatoid arthritis (RA) treatment Xeljanz.

The US pharma firm filed a case last month against Sun Pharma claiming infringement of its patents and sought to injunct the Indian drug maker from developing the compound, but no injunction has as yet been granted. On Aug 24, Pfizer questioned if Sun Pharmahad launched the product in the domestic market.

Revenue rises at Pfizer as Ibrance and Xeljanz beat sales expectations

Pfizer has published its Q2 results, which show revenues rising 11% with new drugs helping to drive the growth and offset falling sales for its blockbuster vaccine, Prevnar.

Ulcerative colitis treatment Xeljanz records positive top-line results in Phase III trial

Pfizer has announced positive top-line results from oral clinical trials for tofacitinib in ulcerative colitis (Octave) sustain, the third Phase III of Xeljanz (tofacitinib citrate), a treatment for patients suffering from moderate to severely active ulcerative colitis (UC).

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches